Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, …
Over the last 12 months, insiders at Abbott Laboratories have bought $0 and sold $44.02M worth of Abbott Laboratories stock.
On average, over the past 5 years, insiders at Abbott Laboratories have bought $249,900 and sold $63.74M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,040 shares for transaction amount of $249,900 was made by Kumbier Michelle (director) on 2021‑02‑23.
2024-10-21 | Sale | EXECUTIVE VICE PRESIDENT | 157,421 0.0091% | $117.04 | $18.42M | -0.91% | ||
2024-09-12 | Sale | CHAIRMAN AND CEO | 141,679 0.0081% | $116.41 | $16.49M | -0.80% | ||
2024-09-04 | Sale | VICE PRESIDENT | 27 <0.0001% | $114.83 | $3,100 | +1.32% | ||
2024-05-10 | Sale | EXECUTIVE VICE PRESIDENT | 10,097 0.0006% | $104.57 | $1.06M | +7.03% | ||
2024-05-07 | Sale | EXECUTIVE VICE PRESIDENT | 22,852 0.0013% | $106.25 | $2.43M | +5.16% | ||
2024-03-01 | Sale | EXECUTIVE VICE PRESIDENT | 853 <0.0001% | $118.50 | $101,081 | -6.18% | ||
2024-03-01 | Sale | EXECUTIVE VICE PRESIDENT | 963 <0.0001% | $118.50 | $114,116 | -6.18% | ||
2024-03-01 | Sale | EXECUTIVE VICE PRESIDENT | 676 <0.0001% | $118.50 | $80,106 | -6.18% | ||
2024-03-01 | Sale | EXECUTIVE VICE PRESIDENT | 694 <0.0001% | $118.50 | $82,239 | -6.18% | ||
2024-03-01 | Sale | EXECUTIVE VICE PRESIDENT | 801 <0.0001% | $118.50 | $94,919 | -6.18% | ||
2024-03-01 | Sale | VICE PRESIDENT | 472 <0.0001% | $118.50 | $55,932 | -6.18% | ||
2024-02-23 | Sale | EXECUTIVE VICE PRESIDENT | 12,500 0.0007% | $120.00 | $1.5M | -6.69% | ||
2024-01-29 | Sale | EXECUTIVE VICE PRESIDENT | 17,500 0.001% | $112.50 | $1.97M | -1.06% | ||
2023-12-14 | Sale | EXECUTIVE VICE PRESIDENT | 15,000 0.0009% | $108.00 | $1.62M | +3.36% | ||
2023-10-26 | Sale | director | 50,000 0.0029% | $94.05 | $4.7M | +17.07% | ||
2023-08-08 | Sale | EXECUTIVE VICE PRESIDENT | 10,400 0.0006% | $105.03 | $1.09M | -0.28% | ||
2023-07-27 | Sale | director | 50,000 0.0029% | $113.76 | $5.69M | -9.47% | ||
2023-06-16 | Sale | VICE PRESIDENT | 8,000 0.0005% | $106.00 | $848,000 | +0.61% | ||
2023-05-02 | Sale | director | 50,000 0.0029% | $111.02 | $5.55M | -3.58% | ||
2023-05-02 | Sale | EXECUTIVE VICE PRESIDENT | 8,226 0.0005% | $110.56 | $909,472 | -3.58% |
Ford Robert B | CHAIRMAN AND CEO | 220059 0.0127% | $117.41 | 1 | 4 | +25.56% |
STARKS DANIEL J | director | 6725316 0.3877% | $117.41 | 1 | 6 | +9.73% |
WHITE MILES D | Chairman and CEO | 3174165 0.183% | $117.41 | 2 | 20 | +6.88% |
Fussell Stephen R | Executive Vice President | 169935 0.0098% | $117.41 | 1 | 44 | +19.09% |
Blaser Brian J | Executive Vice President | 130745 0.0075% | $117.41 | 1 | 23 | +28.16% |
The Vanguard Group | $18.79B | 9.5 | 165.3M | +5.65% | +$1B | 0.35 | |
BlackRock | $15.13B | 7.65 | 133.08M | -0.74% | -$112.33M | 0.33 | |
Capital Research Global Investors | $9.55B | 4.83 | 83.98M | -3.01% | -$295.96M | 2.16 | |
State Street | $8.49B | 4.3 | 74.74M | +0.07% | +$5.85M | 0.35 | |
Capital International Investors | $7.98B | 4.03 | 70.18M | +9.15% | +$668.64M | 1.62 |